glp-1 microdose Microdosing Microdosing GLP-1

Administering a GLP-1 agonist affects multiple organs simultaneously, explaining secondary benefits like reduced appetite, cardiovascular improvements, and kidney protection

Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y, et al

[DOI] [PMC free article] [PubMed] [Google Scholar] 98.Mishra R, Raj R, Elshimy G, Zapata I, Kannan L, Majety P, et al

This approval is important because it recognizes that a GLP-1 receptor agonist can have a role beyond appetite and weight management for a specific liver-disease population

With just 13 states electing to cover GLP-1s for the treatment of obesity alone, low-income earners in the rest of the country are left paying out of pocket

Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study